1. Enoxaparin titrated by anti-Xa levels reduces venous thromboembolism in trauma patients
- Author
-
Bryan R. Collier, Rebecca Gates, Emily R. Faulks, Daniel I Lollar, Jacob Smith, and Jacob Gillen
- Subjects
Male ,medicine.medical_specialty ,Hemorrhage ,Critical Care and Intensive Care Medicine ,Chemoprevention ,Internal medicine ,Outcome Assessment, Health Care ,Humans ,Medicine ,Drug Dosage Calculations ,Registries ,cardiovascular diseases ,Dosing ,Enoxaparin ,Risk factor ,Dose-Response Relationship, Drug ,business.industry ,Incidence ,Incidence (epidemiology) ,Trauma quality improvement program ,Venous Thromboembolism ,Middle Aged ,equipment and supplies ,medicine.disease ,Quality Improvement ,Thrombosis ,Pulmonary embolism ,Regimen ,Factor Xa ,Chemoprophylaxis ,Wounds and Injuries ,Female ,Risk Adjustment ,Surgery ,Blood Coagulation Tests ,Drug Monitoring ,Pulmonary Embolism ,business ,Factor Xa Inhibitors - Abstract
Trauma is a major risk factor for the development of a venous thromboembolism (VTE). After observing higher than expected VTE rates within our center's Trauma Quality Improvement Program data, we instituted a change in our VTE prophylaxis protocol, moving to enoxaparin dosing titrated by anti-Xa levels. We hypothesized that this intervention would lower our symptomatic VTE rates.Adult trauma patients at a single institution meeting National Trauma Data Standard criteria from April 2015 to September 2019 were examined with regards to VTE chemoprophylaxis regimen and VTE incidence. Two groups of patients were identified based on VTE protocol-those who received enoxaparin 30 mg twice daily without routine anti-Xa levels ("pre") versus those who received enoxaparin 40 mg twice daily with dose titrated by serial anti-Xa levels ("post"). Univariate and multivariate analyses were performed to define statistically significant differences in VTE incidence between the two cohorts.There were 1698 patients within the "pre" group and 1406 patients within the "post" group. The two groups were essentially the same in terms of demographics and risk factors for bleeding or thrombosis. There was a statistically significant reduction in VTE rate (p = 0.01) and deep vein thrombosis rate (p = 0.01) but no significant reduction in pulmonary embolism rate (p = 0.21) after implementation of the anti-Xa titration protocol. Risk-adjusted Trauma Quality Improvement Program data showed an improvement in rate of symptomatic pulmonary embolism from fifth decile to first decile.A protocol titrating prophylactic enoxaparin dose based on anti-Xa levels reduced VTE rates. Implementation of this type of protocol requires diligence from the physician and pharmacist team. Further research will investigate the impact of protocol compliance and time to appropriate anti-Xa level on incidence of VTE.Therapeutic/care management, Level IV.
- Published
- 2021
- Full Text
- View/download PDF